You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey

Last Updated: September 29, 2023

Investigational Drug Information for Prexasertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 18 clinical trials for Prexasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.

The most common disease conditions in clinical trials are Neoplasms, Neoplasm Metastasis, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaGOG FoundationPhase 1/Phase 2
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaAcrivon TherapeuticsPhase 1/Phase 2
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaMemorial Sloan Kettering Cancer CenterPhase 1/Phase 2

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib ⤷  Try a Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) ⤷  Try a Trial
Prexasertib ⤷  Try a Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Try a Trial
Prexasertib ⤷  Try a Trial 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Prexasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Prexasertib Argentina AR106772 2035-12-07 ⤷  Try a Trial
Prexasertib Australia AU2016367041 2035-12-07 ⤷  Try a Trial
Prexasertib Brazil BR112018008398 2035-12-07 ⤷  Try a Trial
Prexasertib Canada CA3003914 2035-12-07 ⤷  Try a Trial
Prexasertib Chile CL2018001432 2035-12-07 ⤷  Try a Trial
Prexasertib China CN108349948 2035-12-07 ⤷  Try a Trial
Prexasertib Colombia CO2018005676 2035-12-07 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.